Landos Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Landos Biopharma's earnings are forecast to decline at 37.1% per annum. Der Gewinn pro Aktie wird voraussichtlich wachsen um 37.6% pro Jahr.

Wichtige Informationen

-37.1%

Wachstumsrate der Gewinne

37.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.6%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	24 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Landos Biopharma posts positive outcome from omilancor End-of-Phase 2 FDA meeting

Jun 14

Landos Biopharma (LABP) Investor Presentation - Slideshow

Jun 08

We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully

May 04

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:LABP - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	N/A	-45	N/A	N/A	1
12/31/2024	N/A	-26	N/A	N/A	1
3/31/2024	N/A	-25	-21	-21	N/A
12/31/2023	N/A	-22	-20	-20	N/A
9/30/2023	N/A	-21	-19	-19	N/A
6/30/2023	N/A	-23	-25	-25	N/A
3/31/2023	N/A	-30	-37	-37	N/A
12/31/2022	N/A	-39	-46	-46	N/A
9/30/2022	N/A	-54	-54	-54	N/A
6/30/2022	N/A	-59	-59	-58	N/A
3/31/2022	18	-43	-31	-31	N/A
12/31/2021	18	-38	-28	-27	N/A
9/30/2021	18	-30	-24	-23	N/A
6/30/2021	18	-25	-17	-17	N/A
3/31/2021	N/A	-34	-32	-32	N/A
12/31/2020	N/A	-30	-23	-23	N/A
9/30/2020	N/A	-22	-17	-17	N/A
6/30/2020	N/A	-17	-16	-16	N/A
3/31/2020	N/A	-16	-12	-12	N/A
12/31/2019	N/A	-13	-10	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: LABP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: LABP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: LABP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von LABP schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: LABP wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von LABP in 3 Jahren voraussichtlich hoch sein wird

Landos Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 52% to US$5.00

Price target decreased by 48% to US$0.55

Price target decreased by 48% to US$0.55

Price target increased by 82% to US$2.00

Price target decreased to US$1.10

Price target decreased to US$18.82

Recent updates

Landos Biopharma Files Form 15

Landos Biopharma, Inc. Announces Board and Executive Changes

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Landos Biopharma, Inc., Annual General Meeting, May 23, 2024

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

New minor risk - Share price stability

Landos Biopharma, Inc. Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis

Landos Biopharma to Present At the American College of Gastroenterology 2023 Annual Scientific Meeting

Landos Biopharma, Inc. Announces Resignation of Patrick Truesdell as Principal Accounting Officer, Patrick Truesdell Remain with Company Until November 10, 2023

Price target decreased by 52% to US$5.00

Landos Biopharma, Inc. Appoints Alka Batycky to its Board of Directors and Audit Committee

Price target decreased by 48% to US$0.55

Price target decreased by 48% to US$0.55

Price target increased by 82% to US$2.00

Landos Biopharma, Inc. announced that it expects to receive $16.690909 million in funding from Perceptive Advisors LLC

Nasdaq Grants Landos Biopharma an Additional 180-Calendar Day Compliance Period to Regain Compliance with the Minimum Bid Price Requirement

Price target decreased to US$1.10

High number of new and inexperienced directors

Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer

Landos Biopharma appoints Fabio Cataldi as Chief Medical Officer

Companies Like Landos Biopharma (NASDAQ:LABP) Could Be Quite Risky

Landos Biopharma, Inc. Reports Positive Top-Line Results from NX-13 Phase 1B Trial

High number of new and inexperienced directors

High number of new and inexperienced directors

Landos Biopharma, Inc.(NasdaqGM:LABP) dropped from Russell 2000 Growth Index

Landos Biopharma, Inc. Names Gregory Oakes as Chief Executive Officer

Landos Biopharma Receives Non-Compliance Letter from Nasdaq

Landos Biopharma, Inc. Announces Executive Changes

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

Price target decreased to US$18.82

High number of new and inexperienced directors

Roderick Wong Not Stand for Re-Election as Director of the Landos Biopharma, Inc

Price target decreased to US$18.82

Dr. Raquel Hontecillas, the Chief Scientific Officer of Landos Biopharma, Inc. Is No Longer with the Company

High number of new and inexperienced directors

Insider notifies of intention to sell stock

Insider recently sold US$456k worth of stock

Insider recently sold US$645k worth of stock

Insider recently sold US$364k worth of stock

Landos Biopharma (NASDAQ:LABP) Is In A Strong Position To Grow Its Business

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Independent Director Konstantin Poukalov has left the company

Landos Biopharma’S Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation At the United European Gastroenterology Week 2021

Landos Biopharma, Inc.(NasdaqGM:LABP) dropped from Russell Microcap Value Index

Landos Biopharma, Inc. Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis Patients

Landos Biopharma posts positive outcome from omilancor End-of-Phase 2 FDA meeting

Landos Biopharma (LABP) Investor Presentation - Slideshow

Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate-to-Severe Crohn’s Disease

We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully

Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis

Landos Biopharma Announces Positive Results from A Phase 1 Study of NX-13 in Healthy Volunteers

Landos Biopharma, Inc. has completed an IPO in the amount of $100 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken